Hikma appoints Robert Pickering to board
This article was originally published in Scrip
Generics developer Hikma Pharmaceuticals has named Robert Pickering an independent non-executive director effective 1 September. Mr Pickering retired in 2008, having spent 23 years at Cazenove & Co., becoming the first CEO of Cazenove Group in 2001, and also serving as CEO of JP Morgan Cazenove, a joint venture partnership.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.